Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Pfizer doses first patient in investigational haemophilia drug trial

A number of treatments on the market are designed to replace factor VII, including both short-acting and newer long-acting versions such as Shire’s Adynovate, Biogen’s Eloctate,

Latest news

New data reinforces safety profile of Roche’s Hemlibra

s Eloctate, Bayer’s Kovaltry and CSL Behring’s Afstyla.
Dupixent drives Sanofi again, but other new drugs are lagging

There was bad news for Genzyme’s blood disorders unit, however. Long-acting haemophilia A drug Eloctate – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – succumbed ... Sanofi took a hefty 1.8bn charge on its books in
EMA clears Novo Nordisk’s long-acting haemophilia A drug

Takeda’s Shire unit already has a long-acting factor VIII product on the market in Adynovate, as does Sanofi with Eloctate from its recent Bioverativ acquisition, Bayer with Kovaltry, and
Sanofi exits R&D pact with Alnylam on rare disease

Haemophilia and other rare blood diseases have become key therapeutic targets for Sanofi in the wake of its acquisition of Bioverativ – which gave it long-acting clotting factor therapies Eloctate and
Sanofi extends growth spurt thanks to Genzyme, Dupixent

While growth for haemophilia treatments Eloctate and Alprolix – acquired as part of Sanofi’s $11.9bn acquisition of Bioverativ last year – remained fairly sluggish, the quarter was marked first sales contribution ... Eloctate and Alprolix grew 4%

More from news
Approximately 3 fully matching, plus 28 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... disorders. During 2016 Eloctate and Alprolix

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...